Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Obstetrics and Gynecology

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.AOG.0000131620.67911.03PMID 15291996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Endometrial Adenocarcinoma Cells ( Ishikawa Line ) Stimulatory Effects of 4-Hydroxytamoxifen on Proliferation of Updated Version

  2006cited by this paper
• Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma.

  2004cited by this paper
• Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.

  2004cited by this paper
• Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.

  2004cited by this paper
• Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone; a case controlled study

  2004cited by this paper
• The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.

  2002cited by this paper
• Tamoxifen induction of angiogenic factor expression in endometrium

  2002cited by this paper
• Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study

  2002cited by this paper
• Association of tamoxifen and uterine sarcoma.

  2002cited by this paper
• Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium.

  2002cited by this paper
• Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.

  2002cited by this paper
• Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer

  2001cited by this paper
• Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer

  2001cited by this paper
• Side effects of adjuvant treatment of breast cancer.

  2001cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen.

  1998cited by this paper
• Estrogen Response Elements Can Mediate Agonist Activity of Anti-estrogens in Human Endometrial Ishikawa Cells*

  1998cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen

  1994cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.

  1994cited by this paper
• Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen.

  1994cited by this paper
• High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.

  1993cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Correlation of ultrasound findings and endometrial histopathology in postmenopausal women.

  1990cited by this paper
• On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study.

  1987cited by this paper
• Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens.

  1985cited by this paper
• Second cancer following cancer of the breast in Connecticut, 1935-82.

  1985cited by this paper

• The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder

  2021cites this paper
• The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?

  2019cites this paper
• Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.

  2017cites this paper
• The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer

  2016cites this paper
• Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study.

  2016cites this paper
• Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.

  2014cites this paper
• Second malignancies after breast cancer: The impact of adjuvant therapy.

  2014cites this paper
• [Tamoxifen and endometrial disease in patients with breast cancer].

  2013cites this paper
• Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings

  2013cites this paper
• The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

  2011cites this paper
• Relationship between tamoxifen use and high risk endometrial cancer histologic types.

  2009cites this paper
• Tamoxifen: to use or not to use.

  2008cites this paper
• Breast cancer risk factors and second primary malignancies among women with breast cancer

  2007cites this paper
• Tamoxifen Use and Impact on the Incidence of Endometrial Carcinoma: Should Tamoxifen use be discontinued?

  2006cites this paper
• Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

  2005cites this paper
• Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?

  2005cites this paper
• Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?

  2005cites this paper
• Endometrial cancer.

  2005cites this paper
• Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma

  2004cites this paper